Back to User profile » Dr Fabrizio Cantini
Papers published by Dr Fabrizio Cantini:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data
Benucci M, Damiani A, Li Gobbi F, Grossi V, Infantino M, Manfredi M, Niccoli L, Cantini F
Therapeutics and Clinical Risk Management 2020, 16:287-297
Published Date: 16 April 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
Degli Esposti L, Perrone V, Sangiorgi D, Alessandrini D, Buda S, Cantini F, Mazzini E, Toma C, De Solda F
Patient Preference and Adherence 2019, 13:187-194
Published Date: 22 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Li Gobbi F, Cassarà E, Kaloudi O, Cantini F
Therapeutics and Clinical Risk Management 2018, 14:2097-2111
Published Date: 24 October 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Focus on biosimilar etanercept – bioequivalence and interchangeability
Cantini F, Benucci M
Biologics: Targets and Therapy 2018, 12:87-95
Published Date: 30 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C
Biologics: Targets and Therapy 2013, 7:1-6
Published Date: 4 January 2013
![Noteworthy comment: This study demonstrates that halving the dose of adalimumab used for the treatment of psoriatic arthritis (PsA) maintains drug efficacy, reduces drug exposure risks and affords cost savings. Clinical remission was achieved in a high percentage of patients with early PsA. In contrast to patients with rheumatoid arthitis, a high proportion of PsA patients maintained remission over a long-term follow-up.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C
Biologics: Targets and Therapy 2012, 6:201-206
Published Date: 12 July 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients
Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I
Biologics: Targets and Therapy 2012, 6:5-12
Published Date: 29 December 2011